Neuropeptide systems in social behavior
Chair: James L. Goodson, Indiana University, USA

14.00  Sociality and subordinance: Behavioral regulation by functionally opposed vasotocin/vasopressin cell groups in songbirds and rodents
James L. Goodson, Indiana University, USA
14.30  Getting caught in peculiar positions: Variation in the mechanisms of monogamy
Steven M. Phelps, University of Florida, USA
15.00  Does vasopressin regulate intermale aggression?  Intracerebral vasopressin release during resident-intruder encounters gives new insights
Alexa Veenema, University of Massachusetts, USA
15.30  Seasonal shifts in vasotocin influences on social approach are associated with receptor regulation in the hindbrain
Richmond R. Thompson, Bowdoin College Maine, USA

Feeding behavior and appetite
Chair:  Richard Hargreaves, Merck, USA

16.30  Regulation of food intake by xenin
Tooru Mizuno, University of Manitoba, Canada
17.00  Central nutrient sensing engages forebrain and hindbrain neuropeptide systems in the control of energy balance
Gary J. Schwartz, Albert Einstein College of Medicine, USA
17.30  The role of GLP-1 in regulating glucose homeostasis: CNS vs. peripheral actions
Darleen Sandoval, University of Cincinnati, USA

Emerging neuropeptide systems
Chair:  Andrew Russo, University of Iowa, USA

09.00  Rethinking the mechanism of action for oxytocin effects on CNS function
Robert H. Ring, Wyeth, USA
09.30  Pharmacology and genetics of the Neuropeptide S system
Rainer K. Reinscheid, University of California Irvine, USA
10.00  Neurotensin: It's not your father's therapeutic target
David Feifel, University of California San Diego, USA

The role of neuropeptides in neuronal plasticity
Chair  Richard Miller, Northwestern University, USA

11.00  Roles of PACAP signalling in mouse neurogenesis
Sanbing Shen, University of Aberdeen, UK
11.30  The dual role of neuropeptide co-transmitters: regulation of synaptic transmission and neurogenesis
Helen Scharfman, New York University, USA
12.00  Regulation of adult hippocampal neurogenesis by the SDF-1-chemokine receptors CXCR4 and CXCR7
Ralf Stumm, Otto von Guericke University of Magdeburg, Germany

Neurogenic inflammation and pain
Chair:  Robert H. Ring, Wyeth, USA

13.30  A potential preclinical migraine model: CGRP-sensitized mice
Andrew Russo, University of Iowa, USA
14.00  Pronociceptive role of chemokine receptors in models of chronic pain
Fletcher A. White, Loyola University of Chicago, USA
14.30  Pro-nociceptive activity of neuropeptides sustain chronic pain
Frank Porreca, University of Arizona, USA

15.30  Hot Topics
Chair:  David Bleakman, Eli Lilly and Company, USA

15.30 Maternal separation impairs social recognition due to a lack of septal vasopressin responsiveness in adult male rats
Michael Lukas, University of Regensburg, Germany

15.45 Central actions of the oligosomatostatin receptor agonist ODT8-SST: increase of food intake and decrease of body weight
Tamer Coskun, Eli Lilly and Company Research Laboratories, USA

16.00 Newly-elucidated neuropeptides in the hippocampus: The role of the teneurin C-terminal associated peptides (TCAPs) on stress-related pathways AND Localization and characterization of teneurin C-terminal associated peptide (TCAP) expression in mouse brain
Laura Tan and Dhan Chand, University of Toronto, Canada

16.15 The role of arginine vasopressin and oxytocin within the nucleus accumbens during environment elicited cocaine-conditioned response
Enriqu Rodriguez, University of Puerto Rico, Puerto Rico

16.30 Corticotropin releasing factor receptors-1 are implicated in the sensory component of inflammatory and neuropathic pain
M Hummel, Wyeth Research, USA

16.45 Anticonvulsant and analgesic profile of NAX-5055: A high affinity, metabolically stable, and blood-brain-barrier penetrant galanin-based analog
E Adkins-Scholl, University of Utah, USA

17.00 Sleep promotion induced by orexin-2 receptor antagonism in the rat is diminished by orexin-1 receptor blockade
Jonathan Shelton, Johnson and Johnson PRDUS, USA

17.15 Voluntary exercise and effects on Urocortin 1 and brain derived neurotrophic factor expression in the mouse brain
Susanne Hilke, Linköping University Hospital, Sweden

17.30 Virus-based targeting of oxytocin and vasopressin neurons: a new tool for functional anatomy and physiology of hypothalamic neuropeptides
Valery Grinevich, Max-Planck-Institute for Medical Research, Germany

17.45 Intranasal oxytocin augmentation of antipsychotic medication in schizophrenia patients
David Feifel, University of California San Diego, USA

Arousal and sleep
Chair:  Darryle Schoepp, Merck, USA

09.00  Afferent control of hypocretin neurons: implications for sleep and arousal
Thomas S. Kilduff, SRI International, USA
09.30  Hypocretins: master regulators of arousal
Luis de Lecea, Stanford School of Medicine, USA
10.00  In vivo characterization of novel dual orexin receptor antagonists
Christopher J. Winrow, Merck, USA

Neuropeptidergic control of stress responsivity
Chair:  Craig Ferris, Northeastern University, USA

11.00  Brain oxytocin and prolactin: control of behavioural, neuroendocrine and neuronal stress responses
Inga D. Neumann, University of Regensburg, Germany
11.30  Neuropeptides in the amygdala: significance for fear expression, memory and extinction
Hans-Christian Pape, University of Münster, Germany
12.00  Neuropeptidergic modulation of distinct aspects of the fear e: in vitro and in vivo effects of oxytocin
Ron Stoop, University of Lausanne, Switzerland

Imaging of neuropeptidergic action in the CNS
Chair  Inga D. Neumann, University of Regensburg, Germany

13.30  Functional MRI studies on aggression and fear conditioning using a selective vasopressin V1a receptor antagonist
Craig Ferris, Northeastern University, USA
14.00  Imaging neuropeptidergic function in the maternal brain
Marcelo Febo, Northeastern University, USA
14.30  PET and SPECT imaging using neuropeptides
Gilles Tamagnan, Molecular Neuroimaging LLC, USA

Lessons learned from translation
Chair:  Menelas Pangalos, Wyeth, USA

15.30  Biomarkers to establish brain activity of neuropeptides in humans
William Z. Potter, Merck, USA
16.00  Recent advances in developing neuropeptide receptor ligands to treat psychiatric diseases
Ceri H. Davies, GlaxoSmithKline, UK
16.30  The role of corticotropin-releasing factor circuits in the pathophysiology of depression: implications for CRF receptor antagonists as novel antidepressants
Charles Nemeroff, Emory University School of Medicine, USA
17.00  Clinical development of SSR149415, a selective, nonpeptide, vasopressin V1b receptor antagonist
Lisa Arvanitis, Sanofi-Aventis, USA